Shoiab Bukhari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoiab Bukhari has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Raies Ahmad Qadri
Immunobiology Lab, Department of Biotechnology, University of Kashmir, Srinagar, India
4 shared publications - Taseem Ahmad Mokhdomi
Department of Biotechnology University of Kashmir Srinagar India
4 shared publications Asif Amin
Department of Biotechnology, University of Kashmir, Srinagar India :
3 shared publications- Asrar H. Wafai
University of Kashmir, Srinagar, J & K, India
2 shared publications - Yevgeniya Gartshteyn
Y. Gartshteyn, MD, Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, New York, USA
2 shared publications Zubair Wani
Department of Biotechnology University of Kashmir Srinagar India
2 shared publications
Latest Publications
- Open Access
- 21 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010758
Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells
Objective: Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T RM ) significantly eliminates cancer cells and is associated with irAE-related colitis and dermatitis. However, it remains unknown why the development of these irAEs is restricted to a subset of patients. We hypothesized that osteoarthritis (OA) associated tissue damage and chronic inflammation lead to the recruitment and differentiation of joint T RM cells, predisposing individuals to ICI-induced arthritis. Methods: Using a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis. Results: Our findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T RM cells expressing programmed cell death protein-1 (PD-1) were the predominant synovial T cells in OA joints. These cells were directly targeted by ICIs, resulting in an inflammatory immune response and the transition from OA to irAE-arthritis. Conclusion: This study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T RM cells in OA joints, resulting in tissue inflammation and irAE-arthritis. This research could significantly enhance the management and treatment of patients with cancer receiving ICIs.
- 21 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010758
Open AccessOsteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells
Objective: Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T RM ) significantly eliminates cancer cells and is associated with irAE-related colitis and dermatitis. However, it remains unknown why the development of these irAEs is restricted to a subset of patients. We hypothesized that osteoarthritis (OA) associated tissue damage and chronic inflammation lead to the recruitment and differentiation of joint T RM cells, predisposing individuals to ICI-induced arthritis. Methods: Using a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis. Results: Our findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T RM cells expressing programmed cell death protein-1 (PD-1) were the predominant synovial T cells in OA joints. These cells were directly targeted by ICIs, resulting in an inflammatory immune response and the transition from OA to irAE-arthritis. Conclusion: This study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T RM cells in OA joints, resulting in tissue inflammation and irAE-arthritis. This research could significantly enhance the management and treatment of patients with cancer receiving ICIs.
- Open Access
- 8 December 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (2) , e202201533
SLAMF6 compartmentalization enhances T cell functions
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic target, we investigated how its compartmentalization on the cell surface affects T cell functions. We used biochemical and co-culture assays to show that T cell activity is enhanced when SLAMF6 colocalizes with the CD3 complex. Mechanistically, co-immunoprecipitation analysis revealed the SLAMF6-interacting proteins to be those essential for signaling downstream of T cell receptor, suggesting the two receptors share downstream signaling pathways. Bispecific anti-CD3/SLAMF6 antibodies, designed to promote SLAMF6 clustering with CD3, enhanced T cell activation. Meanwhile, anti-CD45/SLAMF6 antibodies inhibited SLAMF6 clustering with T cell receptor, likely because of the steric hindrance, but nevertheless enhanced T cell activation. We conclude that SLAMF6 bispecific antibodies have a role in modulating T cell responses, and future work will evaluate the therapeutic potential in tumor models.
- 8 December 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (2) , e202201533
Open AccessSLAMF6 compartmentalization enhances T cell functions
Signaling lymphocyte activation molecule family member 6 (SLAMF6) is a T cell co-receptor. Previously, we showed that SLAMF6 clustering was required for T cell activation. To better understand the relationship between SLAMF6 location and function and to evaluate the role of SLAMF6 as a therapeutic target, we investigated how its compartmentalization on the cell surface affects T cell functions. We used biochemical and co-culture assays to show that T cell activity is enhanced when SLAMF6 colocalizes with the CD3 complex. Mechanistically, co-immunoprecipitation analysis revealed the SLAMF6-interacting proteins to be those essential for signaling downstream of T cell receptor, suggesting the two receptors share downstream signaling pathways. Bispecific anti-CD3/SLAMF6 antibodies, designed to promote SLAMF6 clustering with CD3, enhanced T cell activation. Meanwhile, anti-CD45/SLAMF6 antibodies inhibited SLAMF6 clustering with T cell receptor, likely because of the steric hindrance, but nevertheless enhanced T cell activation. We conclude that SLAMF6 bispecific antibodies have a role in modulating T cell responses, and future work will evaluate the therapeutic potential in tumor models.
- 4 January 2021
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 122 (5) , 562-576
Lung cancer cell‐derived EDA‐containing fibronectin induces an inflammatory response from monocytes and promotes metastatic tumor microenvironment
Tumor‐associated macrophages (TAMs) play a pivotal role in facilitating tumor growth and metastasis. This tumor‐promoting propensity of TAMs sets in as a result of their complex cross‐talk with tumor cells mediated primarily by tumor cell‐secreted proteins in the tumor microenvironment. To explore such interactions, we employed an immunoscreening approach involving the immunization of Balb‐c mice with model human lung carcinoma cell line, A549. From serological examination combined with mass spectrometric analysis, EDA‐containing fibronectin (EDAFN) was identified as a conspicuous immunogenic protein in A549 cell secretome. We showed that A549 secreted EDAFN engages TLR‐4 on THP‐1 monocytes to drive the proinflammatory response via NF‐κB signaling cascade. Conversely, A549 derived EDAFN potentiates their metastatic capacity by inducing epithelial–mesenchymal transition through its autocrine activity. In conclusion, the study proposes a possible mechanism of cellular cross‐talk between lung cancer cells and associated monocytes mediated by lung cancer‐derived EDAFN and resulting in the establishment of proinflammatory and metastatic tumor microenvironment.
- 4 January 2021
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 122 (5) , 562-576
Lung cancer cell‐derived EDA‐containing fibronectin induces an inflammatory response from monocytes and promotes metastatic tumor microenvironment
Tumor‐associated macrophages (TAMs) play a pivotal role in facilitating tumor growth and metastasis. This tumor‐promoting propensity of TAMs sets in as a result of their complex cross‐talk with tumor cells mediated primarily by tumor cell‐secreted proteins in the tumor microenvironment. To explore such interactions, we employed an immunoscreening approach involving the immunization of Balb‐c mice with model human lung carcinoma cell line, A549. From serological examination combined with mass spectrometric analysis, EDA‐containing fibronectin (EDAFN) was identified as a conspicuous immunogenic protein in A549 cell secretome. We showed that A549 secreted EDAFN engages TLR‐4 on THP‐1 monocytes to drive the proinflammatory response via NF‐κB signaling cascade. Conversely, A549 derived EDAFN potentiates their metastatic capacity by inducing epithelial–mesenchymal transition through its autocrine activity. In conclusion, the study proposes a possible mechanism of cellular cross‐talk between lung cancer cells and associated monocytes mediated by lung cancer‐derived EDAFN and resulting in the establishment of proinflammatory and metastatic tumor microenvironment.
- Open Access
- 18 May 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (9) , 3691-3696
Comparative proteomics and global genome-wide expression data implicate role of ARMC8 in lung cancer
Cancer loci comprise heterogeneous cell populations with diverse cellular secretions. Therefore, disseminating cancer-specific or cancer-associated protein antigens from tissue lysates could only be marginally correct, if otherwise not validated against precise standards. In this study, 2DE proteomic profiles were examined from lysates of 13 lung-adenocarcinoma tissue samples and matched against the A549 cell line proteome. A549 matched-cancer-specific hits were analyzed and characterized by MALDI-TOF/MS. Comparative analysis identified a total of 13 protein spots with differential expression. These proteins were found to be involved in critical cellular functions regulating pyrimidine metabolism, pentose phosphate pathway and integrin signaling. Gene ontology based analysis classified majority of protein hits responsible for metabolic processes. Among these, only a single non-predictive protein spot was found to be a cancer cell specific hit, identified as Armadillo repeat-containing protein 8 (ARMC8). Pathway reconstruction studies showed that ARMC8 lies at the centre of cancer metabolic pathways. The findings in this report are suggestive of a regulatory role of ARMC8 in control of proliferation and differentiation in lung adenocarcinomas.
- 18 May 2015
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (9) , 3691-3696
Open AccessComparative proteomics and global genome-wide expression data implicate role of ARMC8 in lung cancer
Cancer loci comprise heterogeneous cell populations with diverse cellular secretions. Therefore, disseminating cancer-specific or cancer-associated protein antigens from tissue lysates could only be marginally correct, if otherwise not validated against precise standards. In this study, 2DE proteomic profiles were examined from lysates of 13 lung-adenocarcinoma tissue samples and matched against the A549 cell line proteome. A549 matched-cancer-specific hits were analyzed and characterized by MALDI-TOF/MS. Comparative analysis identified a total of 13 protein spots with differential expression. These proteins were found to be involved in critical cellular functions regulating pyrimidine metabolism, pentose phosphate pathway and integrin signaling. Gene ontology based analysis classified majority of protein hits responsible for metabolic processes. Among these, only a single non-predictive protein spot was found to be a cancer cell specific hit, identified as Armadillo repeat-containing protein 8 (ARMC8). Pathway reconstruction studies showed that ARMC8 lies at the centre of cancer metabolic pathways. The findings in this report are suggestive of a regulatory role of ARMC8 in control of proliferation and differentiation in lung adenocarcinomas.
- 27 September 2013
- Published by Springer Nature in Journal of Crop Science and Biotechnology
- Vol. 16 (3) , 183-188
Relative expression of apocarotenoid biosynthetic genes in developing stigmas of Crocus sativus L.
- 27 September 2013
- Published by Springer Nature in Journal of Crop Science and Biotechnology
- Vol. 16 (3) , 183-188
Relative expression of apocarotenoid biosynthetic genes in developing stigmas of Crocus sativus L.
- 1 July 2013
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 5 (4) , 170-175
Investigating the pharmacological potential of Iris kashmiriana in limiting growth of epithelial tumors
- 1 July 2013
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 5 (4) , 170-175
Investigating the pharmacological potential of Iris kashmiriana in limiting growth of epithelial tumors